|Mr. Jean-Francois Mouney||Co-Founder & Chairman||331.88k||N/A||1955|
|Mr. M. Pascal Prigent||Chief Exec. Officer||502.94k||N/A||1968|
|Prof. Bart Staels||Co-Founder & Chairman of the Scientific Advisory Board||N/A||N/A||1963|
|Mr. Thomas Baetz||Chief Financial Officer||N/A||N/A||1974|
|Mr. Pascal Caisey||Chief Operating Officer||N/A||N/A||1968|
|Dr. Dean W. Hum Ph.D.||Chief Scientific Officer||N/A||N/A||1962|
|Mr. Laurent Lannoo||Corp. Sec. & Director of Legal Affairs||N/A||N/A||1970|
|Ms. Stefanie Magner||Chief Compliance Officer & VP of International Legal Affairs||N/A||N/A||1981|
|Ms. Emilie Desodt||Vice-Pres of HR||N/A||N/A||1983|
|Mr. Jean-Christophe Marcoux||Chief Strategy Officer||N/A||N/A||1977|
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Genfit SA’s ISS governance QualityScore as of 1 October 2022 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder rights: 4; Compensation: 9.